Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sumeet Chhabra

Clinical Cardiac Electrophysiology Plano, TX Medical Doctor

NPI 1548479827 CMS profile 251903

4708 Alliance Blvd Ste 500, Ste 536, Plano, TX 75093

Open in the dashboard

General payments

$66,475

464 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sumeet Chhabra of Plano, TX is reported in the CMS Open Payments database as having received $66,475 across 464 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,914 84
2024 General $2,854 56
2023 General $2,546 52
2022 General $9,122 60
2021 General $5,882 46
2020 General $13,732 44
2019 General $25,425 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sumeet Chhabra
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Sumeet Chhabra were reported at $6,914. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Sumeet Chhabra Clinical Cardiac Electrophysiology median Middle half National median
2019 $25,425 $2,361 $585–$8,260 $163
2020 $13,732 $993 $247–$4,351 $114
2021 $5,882 $1,185 $326–$4,739 $132
2022 $9,122 $2,073 $554–$6,789 $149
2023 $2,546 $2,568 $759–$8,159 $160
2024 $2,854 $2,557 $703–$7,403 $164
2025 $6,914 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $43,549 111 payments
  2. Biosense Webster, Inc. $8,269 53 payments
  3. Medtronic, Inc. $7,242 97 payments
  4. Medical Device Business Services, Inc. $2,250 7 payments
  5. Medtronic Vascular, Inc. $860 30 payments
  6. Boston Scientific Corporation $808 21 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $733 34 payments
  8. Pfizer Inc. $371 17 payments
  9. Cordis US Corp. $234 3 payments
  10. Janssen Pharmaceuticals, Inc $229 13 payments
  11. Other $1,931 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $29,791 24 payments
  2. Food and Beverage $17,105 411 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $12,000 8 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $4,000 4 payments
  5. Travel and Lodging $2,379 16 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,200 1 payment
Products named General payments · program years 2019–2025
  1. Ensite Cardiac Mapping System $23,848 17 payments
  2. Merlin Connectivity and Remote Cardiac Arrhythmias and Heart Failure $9,184 9 payments
  3. Carto 3 $7,839 30 payments
  4. Merlin Connectivity and Remote Cardiac Rhythm Management $2,617 4 payments
  5. Carto 3 System $2,457 18 payments
  6. EnSite Precision Cardiac Mapping System $1,806 6 payments
  7. Micra $1,560 22 payments
  8. AVEIR $1,035 7 payments
  9. COBALT DR MRI SURESCAN $965 11 payments
  10. Assurity Pacemaker $857 16 payments
  11. Other $11,804 315 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,412

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$733,070

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

47.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 406 $520,481
Xarelto Rivaroxaban Brand 137 $156,976
Multaq Dronedarone Hcl Brand 22 $27,135
Dofetilide Generic 74 $11,346
Mexiletine Hcl Generic 31 $3,861
Flecainide Acetate Generic 77 $3,266
Metoprolol Succinate Generic 161 $2,594
Amiodarone Hcl Generic 66 $1,974
Sotalol Sotalol Hcl Brand 60 $1,203
Esomeprazole Magnesium Generic 25 $740

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$411,384

Medicare's payments for the services billed

Medicare patients

1,006

Average age 78

Services billed

7,019

427 women, 579 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 71%
Ischemic heart disease 50%
Arthritis 50%
Heart failure 43%
Chronic kidney disease 40%
Diabetes 34%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $82
$82 — —
ELIQUIS
  • PFIZER INC. $43
  • E.R. Squibb & Sons, L.L.C. $23
$67 406 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $53
$53 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $23
$23 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

464 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record